Coculture of Marine Invertebrate-Associated Bacteria and Interdisciplinary Technologies Enable Biosynthesis and Discovery of a New Antibiotic, Keyicin

Navid Adnani,[†] Marc G. Chevrette,[‡,§] Srikar N. Adibhatla,[†] Fan Zhang,[†] Qing Yu,[†] Doug R. Braun,[†] Justin Nelson,[∥] Scott W. Simpkins,[∥] Bradon R. McDonald,[‡] Chad L. Myers,[∥,⊥] Jeff S. Piotrowski,[#] Christopher J. Thompson,[7] Cameron R. Currie,[‡] Lingjun Li,[†] Scott R. Rajski,[†] and Tim S. Bugni*,[†]

[†]Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, United States

[‡]Department of Bacteriology, University of Wisconsin, Madison, Wisconsin 53705, United States

[§]Department of Genetics, University of Wisconsin, Madison, Wisconsin 53705, United States

[∥]Bioinformatics and Computational Biology Program, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, United States

[⊥]Department of Computer Science and Engineering, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, United States

[#]Yumanity Therapeutics, Cambridge, Massachusetts 02139, United States

[7]Bruker Daltonics, Billerica, Massachusetts 01821, United States

ⓈSupporting Information

ABSTRACT: Advances in genomics and metabolomics have made clear in recent years that microbial biosynthetic capacities on Earth far exceed previous expectations. This is attributable, in part, to the realization that most microbial natural product (NP) producers harbor biosynthetic machineries not readily amenable to classical laboratory fermentation conditions. Such "cryptic" or dormant biosynthetic gene clusters (BGCs) encode for a vast assortment of potentially new antibiotics and, as such, have become extremely attractive

targets for activation under controlled laboratory conditions. We report here that coculturing of a *Rhodococcus* sp. and a *Micromonospora* sp. affords keyicin, a new and otherwise unattainable bis-nitroglycosylated anthracycline whose mechanism of action (MOA) appears to deviate from those of other anthracyclines. The structure of keyicin was elucidated using high resolution MS and NMR technologies, as well as detailed molecular modeling studies. Sequencing of the keyicin BGC (within the *Micromonospora* genome) enabled both structural and genomic comparisons to other anthracycline-producing systems informing efforts to characterize keyicin. The new NP was found to be selectively active against Gram-positive bacteria including both *Rhodococcus* sp. and *Mycobacterium* sp. *E. coli*-based chemical genomics studies revealed that keyicin's MOA, in contrast to many other anthracyclines, does not invoke nucleic acid damage.

■ INTRODUCTION

It is now widely recognized that humanity faces a host of burgeoning crises likely to impact global health in the foreseeable future. Principal among these has been the rise of drug resistant microbes set forth, in part, by a loss of interest in natural products (NPs) in the 1970s through to the early 2000s across both academia and industry. This change in attitude was inspired by two critical thoughts at the time: (i) the belief that NP structural diversity and microbial diversities had largely been exhausted and (ii) the belief that a more efficient means of identifying drugs and drug leads lay in the prodigious application of combinatorial chemistry and high throughput screening (HTS) technologies. However, our view of drug discovery today is informed largely by technological advances and discoveries over the last 10−20 years that dramatically refute those early tenets and argue that natural products remain one of the greatest sources of molecular diversity applicable to treating human diseases.[1] Revolutionary advances in genome sequencing, proteomics, metabolomics, and other methodologies have changed not only how we see the natural world but also how we can harness its intricacies. The rise of these technologies enabled by technical advances (e.g., those related to nucleic acid and protein sequencing and synthesis, mass spectrometry and other diagnostics) as well as dramatic

increases in computational capabilities have brought about stunning revelations about microbial diversity and how this influences NP production.[2−16] Microbes leverage NPs to interact with their biotic and abiotic environments and, as such, these metabolites have been selected through evolution for biological relevance, often serving as attractive new drug leads.[17−19] Rational discovery strategies with multidisciplinary approaches can be employed to uncover these bioactive molecules at scale.

For over 80 years, culturable microorganisms formed the basis for NP drug discovery providing unique compounds with useful biological activities and medical uses.[1,20] Metagenomic studies of the last 10−15 years have shown, however, that the overwhelming majority of microorganisms (>95%) on earth either have eluded interrogation for NP production, harbor NP biosynthetic gene clusters (BGCs) that remain silent under laboratory culturing conditions, or have been studied using technologies that, at the time, failed to meet the challenges of the day.[21−23] It is believed that only 0.1−1% of the microorganisms on earth have been successfully cultured in the laboratory.[23] At the same time, it is now thought that earth harbors ∼8.7 million eukaryotic species of which about 2.2 million are marine. Similarly, a lower bound of ∼10000 prokaryotic species of which ∼1300 are marine has been postulated.[24] However, microbial diversity assessments employing cultivation-independent technologies suggest that these numbers are likely off by ∼100-fold.[25] For instance, work carried out in support of the International Census of Marine Microbes (ICoMM) initiative has shown that, on average, 1 L of seawater contains 10^8-10^9 bacteria representing ∼20000 bacterial species.[25]

Especially with respect to prokaryotic species and lower eukaryotes, many of these organisms have proven rich sources of NPs (bacteria, fungi, plants, etc.). Yet it is clear that their molecular diversity, especially in light of what we are now learning about microbiomes and symbiotic relationships, remains dramatically underutilized.[26] Genomics has revealed that the untapped microbial diversity available for drug and drug lead identification efforts far exceeds previous expectations.[1,22]

Genome mining using biosynthetic signatures from established BGCs has proven to be an important tool in the search for new antimicrobial NPs, which has inspired an explosion in BGC sequencing efforts and reported NP-encoding genomes.[7,15,27−30] However, identifying new NPs on the basis of BGC mining remains a daunting task; (i) one genome can house multiple, often dozens of BGCs (of the same or different classes), (ii) BGCs might be composed of elements distributed over multiple contigs and may contain genes for which no clear function exists thereby confounding gene-to-reaction correlations, (iii) identified cryptic BGCs may fail to translate to detectable NPs, (iv) many microorganisms are recalcitrant to necessary manipulations, and (v) metagenomic library expression systems are often impractical.[27] Hence, genomic approaches, although an excellent way to identify BGCs and their putative products, are, in the absence of other complementary technologies, insufficient to achieve broadly successful bioinformatics-guided NP identification goals for some biosynthetic classes.[31,32] However, when used in combination with proteomics and metabolomics, genomics becomes an increasingly powerful tool linking molecules with their biosynthetic genes. It is becoming increasingly evident that by triangulating genomic, proteomic, and metabolomic

information for microorganisms one becomes better able to address two key questions in current natural products chemistry: (i) How does one identify interesting organisms when it comes to antimicrobial NP biosynthesis? (ii) How can cryptic BGCs be activated in an otherwise unproductive organism? Interdisciplinary approaches have vastly improved the ability to elucidate biosynthetic potentials; especially those that incorporate biological hypotheses in unveiling novel chemistry.[33] Additionally, chemical genomics (CG) now enables one to rapidly gain insight into a NP's mechanism of action further supporting the notion that biological insight hastens chemical discoveries and can drive chemical initiatives.[34] Conclusively linking a BGC to a NP of interest via genome mining-based approaches remains a challenge. However, recent disclosures, including the efforts detailed here, highlight that genomics, proteomics, and metabolomics can be very effectively leveraged to identify novel producers of unique bioactive NPs.

We report herein the discovery of keyicin (1, Figure 1), a novel poly-nitroglycosylated anthracycline antibiotic, along with


Figure 1. Structure of new coculture-dependent antibiotic keyicin (1).

early efforts to understand its biosynthesis and mechanism(s) of biological activity. An otherwise cryptic NP, keyicin production results from coculturing of the producer *Micromonospora* strain with *Rhodococcus*. Only through the application and synergy of the technologies noted above was the identification and characterization of 1 possible. Closely related NPs have been identified before but never as the products of cocultured microbes nor with zwitterionic nitroglycans appended to the aglycone core. Moreover, a great number of such keyicin-like agents have been shown to express biological activities through DNA-dependent means; results of chemical genomics suggest that keyicin functions in a unique manner that is independent of DNA damage processes. We postulate that keyicin is involved in microbial interactions between the cocultured microbes and that these interactions are representative of similar NP-mediated microbial interactions ubiquitous in nature.[35]

■ RESULTS AND DISCUSSION

Detection of New Antibiotic via Interspecies Interactions. We have previously developed a microscale

coculturing platform to investigate interspecies interactions between marine invertebrate-associated bacteria with a special emphasis on both genomics and metabolomics.[36] Notably, during the course of coculturing *Mycobacterium* sp. with *Micromonospora* WMMB-235, *Mycobacterium* inhibition became evident over time. Coculture-derived antimicrobial activities were selective against the Gram[+] bacteria *Bacillus subtilis* and methicillin-sensitive *Staphylococcus aureus*, as well as *Mycobacterium* sp. and *Rhodococcus* sp. Notably, all coculture systems were characterized by a dark red pigmentation that was absent in corresponding monocultures and, of the coculture systems investigated, the *Micromonospora*−*Rhodococcus* system generated the largest zone of inhibition. Consequently, the *Micromonospora*−*Rhodococcus* coculture system was selected for subsequent metabolomics analysis.

We applied a self-generated in-house LCMS-based metabolomics platform to compare metabolite production between cocultures and monocultures.[36,37] Initial fluctuations in LCMS analyses in replicate cocultures and monocultures were postulated to arise from variable cell concentrations within the seed cultures used to inoculate cocultures. To alleviate such variances, five seed cultures were inoculated and combined (instead of one culture) prior to coculturing (see Methods). Repeated microscale cocultures, using this improved inoculation approach, were evaluated by LCMS−Principal Component Analysis (PCA) metabolomics (Figure 2).[36] In the scores plot, spatial separations of metabolites produced in coculture versus monoculture extracts were observed. Individual metabolites responsible for observed variances were clearly depicted in the loadings plot. Each symbol in the loadings plot corresponds to a retention time (RT)−mass-to-charge (*m/z*) pair. Compounds clustered in the center of the loadings plot

were present in all three strains, while compounds diverging from the cluster represent uniquely produced metabolites. Notably, several compounds were identified as being exclusively produced in coculture (Figure 2).

Having identified the metabolite likely driving coculture antimicrobial activity, we carried out bioactivity-guided fractionation of the coculture extract. A series of related doubly charged ions $[M + 2H]^{2+} = 790.3625, 797.3521$, and 805.3524 amu likely correlating to the antimicrobial species was observed, and extracted ion chromatograms for each mass confirmed that species production was exclusive to the *Micromonospora*−*Rhodococcus* coculture (Supporting Information, Figures S1 and S2). Dereplication concerns dictated that all three masses be queried against the Antibase NP database. The coculture specific species, on the basis of these early efforts, appeared to be previously unreported thus confirming the presumed need to generate keyicin on a scale compatible with complete structural elucidation efforts.

To support structural and mechanistic elucidation efforts both microscale (500 μL) and standard scale (100 mL) fermentations were carried out and sampled daily over a 14 d period.[36] On the basis of LC/MS analyses, keyicin was confirmed to be produced exclusively in coculture regardless of fermentation scale (see Supporting Information) although microscale fermentations afforded keyicin with reduced rates relative to standard scale fermentations. On the basis of these findings, subsequent fermentations were carried out for 14 d. Before transitioning to large scale fermentations, a media study was carried out using four media: ASW-A [20 g soluble starch, 10 g glucose, 5 g peptone, 5 g yeast extract, 5 g CaCO$_3$ in 1 L artificial seawater (ASW)], ASW-D (2 g yeast extract, 5 g malt extract, and 2 g dextrose in 1 L ASW), ISP2 (4 g yeast extract, 10 g malt extract, and 4 g dextrose in 1 L ASW), and M1 (10 g soluble starch, 4 g yeast extract, 2 g peptone, 15 g agar in 1 L ASW). LC/MS analyses indicated that nutrient limited ASW-D media produced the highest yields of keyicin. Hence, large scale cocultures of *Micromonospora* and *Rhodococcus* were carried out for 14 d using ASW-D media enabling sufficient quantities of keyicin to be generated.

Complementary to structure elucidation efforts we also sought to understand the nature of keyicin induction in coculture. Inspired by earlier reports that NP production in cocultures of Actinobacteria and mycolic acid-containing bacteria required physical contact between cell types, we endeavored specifically to determine if keyicin biosynthesis might be triggered by physical cell−cell contact.[38] Employing customized growth flasks separated with a 0.2 μm diffusible membrane monocultures of the *Micromonospora* sp. WMMB-235 and *Rhodococcus sp.* were cultured on either side of the membrane (Figure 3). Daily sampling, plating onto agar, and incubation revealed that (i) indeed, neither cell type could traverse the 0.2 μm membrane and (ii) over the course of 7 d the growth of the *Micromonospora* sp. remained relatively consistent whereas the *Rhodococcus* sp. suffered significant growth inhibition (Figure 3). Most importantly, production of keyicin was observed by LC/MS. Not surprisingly, disc diffusion of keyicin onto lawns of the *Rhodococcus* sp. or *Mycobacterium* sp. WMMA-183 revealed this compound's antibacterial activity, thereby supporting our early observations of growth inhibition during microscale cocultures. On the basis of these findings it was clear that keyicin biosynthesis does not require physical interactions between the *Rhodococcus* "inducing cells" and the putative *Micromonospora* sp. producer of **1**.

Figure 2. LCMS-PCA metabolomics of *Micromonospora* sp. and *Rhodococcus* sp. coculture. (A) PCA scores plot describing variance in metabolites in coculture and monoculture extracts of the *Micromonospora* sp. and *Rhodococcus* sp. (B) PCA loadings plot displaying individual metabolites responsible for the variance observed between extracts; the high variance seen in coculture extracts is attributable to metabolites highlighted by the yellow oval in panel B.

Figure 3. Cell—cell contact study between *Micromonospora* sp. WMMB-235 and *Rhodococcus* sp. WMMA-185. (A1, A2) Each half of custom coculture vessel enabling separation of two independent cultures with 0.2 μm filter. (B) Intact coculture vessel with filter membrane separating cell types. (C) Aliquots of the *Rhodococcus* sp. and (D) aliquots of the *Micromonospora* sp. removed from culture, diluted, and streaked every 2 d.

Characterization of the Keyicin Scaffold. FTICR MS analysis of keyicin (1) revealed its molecular formula to be $C_{75}H_{108}N_4O_{34}$ via isotopic fine structure analysis, and its 2D structure was determined on the basis of extensive ^1H and ^{13}C NMR data sets (Supporting Information). Analysis of ^{13}C NMR data and the red pigment suggested an sp^2 hybridized conjugated carbon skeleton, but only a single aromatic proton, H-3, was observed by ^1H NMR. Additionally, the number of ^{13}C resonances did not match the molecular formula. Only after isotopic labeling with ^{13}C-glucose were all resonances detected. We hypothesize that dynamics on the NMR time scale caused severe broadening of H-11 and affected ^{13}C acquisition in the absence of ^{13}C isotopic labeling. Another potentially confounding feature of keyicin was the presence of eight anomeric protons suggesting a multiply glycosylated aglycone. Given this complexity, it was no surprise that classical 2D NMR experiments, including COSY, HSQC, and HMBC experiments failed to provide much insight into the structure of the keyicin aglycone.

^{13}C isotopic incorporation was evaluated with the goal in mind of executing $^{13}C-^{13}C$ COSY experiments; these would enable us to confidently assign the $^{13}C-^{13}C$ spin system.[7] Optimized ^{13}C incorporation conditions were identified (Supporting Information, Table S2, Figure S5) enabling extensive use of COSY, HMBC, and ROESY approaches to solve the structure of 1.

Analysis of the $^{13}C-^{13}C$ COSY data allowed for rapid characterization of the polycyclic phenolic aglycone. Furthermore, the $^{13}C-^{13}C$ COSY and extensive 1D and 2D NMR data enabled characterization of the eight sugar moieties. The position of H-3 was confirmed using HMBC correlations to C-4a, C-4, C-4′, and C-5′. The C—C spin system beginning with the attachment between C-2 and C-5′, along with HMBC correlation from H-3 to C-4′ and C-5′, indicated a sugar moiety fused to the aglycone. Glycosidic linkages were determined using a combination of HMBC and ROESY correlations to complete the 2D structure of 1 (Figure 4 and Supporting Information).

Strikingly, elucidation of the 2D structure of 1 revealed remarkable similarities, especially with respect to keyicin's aglycone core scaffold, to a number of other NPs whose biosynthetic origins and biological activities are well established. These similarities, especially between the keyicin aglycone, nogalamycin, and aclacinomycin A (Figure 5), would come to greatly expedite our efforts to understand the structure and biosynthetic origins of cryptically encoded NP 1.


Figure 4. Key HMBC (red) and ROESY (blue) correlations in core of 1 and for determination of glycosidic linkages. Carbon connectivities determined by $^{13}C-^{13}C$ COSY correlations. Detailed application of specific ROESY correlations were instrumental in determining S1—S7 configurations (Supporting Information).

Figure 5. Direct comparisons of the keyicin aglycone core to the intact structure of nogalamycin and the more classically arranged anthracycline aclacinomycin A.

The structural relatedness of keyicin and nogalamycin aglycones proved instrumental in establishing the relative configuration of 1. Comparisons of ^{13}C shifts for keyicin to

those previously established for anthracyclines like aclacinomycin A, arugomycin (AGM), and viriplanin A proved instrumental also in elucidating the structures of sugars S1−S7 (Figure 4 for sugar numbering) as did careful evaluation of HMBC and ROESY correlations (Supporting Information Table S1 and Supporting Experimental Procedures). Moreover, S1−S7 were subjected to conformer distribution analyses using Spartan '14 and conformers with a Boltzmann distribution ≥5% were subjected to geometry optimization and ^{13}C NMR calculations.[39] Calculated carbon chemical shifts were compared to experimental values using the DP4 probability method, and the results of these comparisons were used to support or refute configurational assignments made on the basis of ^{13}C chemical shift comparisons to known anthracyclines (see Supporting Information).[40] For the more rigid keyicin aglycone, carbon chemical shifts were calculated using an equilibrium conformer followed by geometry optimization and ^{13}C NMR calculations. Despite the smaller difference between calculated and experimental carbon chemical shifts (Δ) for anthraquinone structure **6** versus **5** (Figure 6), DP4 calculations indicated **5** to be slightly favored over **6** (see Supporting Information Figure S20 for complete analysis).

Figure 6. Partial characterization of anthracycline core possibilities for keyicin via application of molecular modeling and DFT calculation approaches. See Supporting Information for experimental data for these and alternative variants.

However, comparisons of the methyl C-13 chemical shift for similar anthracyclines including nogalamycin (**3**), AGM,[41,42] and viriplanin A[43] suggested that the methyl C-13 was on the opposite side of the plane relative to the C-10 pendant carboxymethyl moiety. Consequently, the keyicin A-ring stereochemistry was ultimately assigned as shown by **6** (see Supporting Information).

Elucidation of keyicin's C1′−C6′ fragment also relied heavily upon comparisons to known anthracyclines. Well established AGM and viriplanins as well as keyicin, all belong to the nogalamycin class of anthracyclines; a key differentiating feature is that nogalamycin itself (**3**) bears only a pendant OH moiety at C4′ site whereas all other members of the class bear O-trisaccharide linkages to C4′. This structural feature of **3** versus all other known members of the nogalamycin class proved instrumental in assigning the C4′ configuration of keyicin.

Comparisons of ^{13}C chemical shifts for C1′−C6′ of the noted anthracyclines suggested identical stereochemistry among the molecules, a notable exception being the *R*-configuration and absence of sugar substitution at C4′ for **3**. Given the high degree of structural similarity between AGM and keyicin, we paid special attention to the ^{13}C shifts for C3′−C6′ keeping in mind the influence that C4′ configuration would have on the surrounding centers. For AGM, these values (C3′ = 62.5, C4′ = 81.6, C5′ = 77.6, C6′ = 23.6 ppm) aligned extremely well with those observed for keyicin (C3′ = 62.7, C4′ = 82.5, C5′ = 78.2, C6′ = 24.2 ppm). In addition, the C3′ pendant N−CH$_3$ resonances for AGM and keyicin at 44.3 and

44.6 ppm, respectively, strongly supported identical C4′ configurations. Given their putatively identical aglycone configuration, AGM served, in comparisons to **3**, as an effective proxy for keyicin. Accordingly, ^{13}C shift differences for C4′ as well as each compounds proximal N−CH$_3$ and C6′ carbon suggested different C4′ configuration between nogalamycin and AGM and, by default, keyicin; differences of 2.4, 1.7, and 1.6 ppm were noted for C4′, N−CH$_3$, and C6′, respectively. These data firmly supported the hypothesis that the aglycones of AGM and keyicin share identical configuration.

That keyicin shares the C4′ *S*-configuration previously demonstrated for AGM and related C4′-glycosylated members of the nogalamycin class was further validated by ROESY. Having defined the relative configuration of all stereocenters in S1 on the basis of ROESY correlations (Supporting Information), we noted a clear ROESY correlation between a C3′ pendant dimethylamine CH$_3$ and the axial anomeric H of S1. This correlation was consistent with a *syn* placement of H3′ and H4′ of the C1′−C6′ tetrahydropyran moiety and ultimate assignment of the *S*-configuration to the keyicin C4′.

Enzymatic studies with **3** have indicated that two enzymes, SnoK and SnoN, are responsible, respectively, for (i) installing the C2−C5′ bond resulting in carbocyclization, and (ii) an epimerization at nogalamycin's C4′ position.[44] Notably, genomic analyses of the keyicin biosynthetic pathway (discussed below) revealed the presence of both *snoK* and *snoN* homologues. Thus, the difference in C4′ configurations between nogalamycin and keyicin may be related to the presence of keyicin's C4′ tethered sugar moiety. We posit that the relative absence of substantive functionality appended to the nogalamycin C4′ enables SnoN-catalyzed epimerization. Conversely, SnoN homologues in the keyicin (and possibly other anthracycline) pathways may not have C4′ access sufficient to permit epimerization.

Having elucidated the structure of **1**, it becomes apparent that a number of interesting features differentiate keyicin from all other related anthracyclines: (i) one of the two polysaccharides projected from the aglycone likely assumes a zwitterionic form under physiologically relevant conditions, and (ii) its construction requires coculture conditions implying that it plays an important and tunable role in bacterial competition or defensive processes; to date there is no evidence to suggest that other related anthracyclines play as important a role in competitive microbe−microbe associations.

Proteomics Analysis of Keyicin-Producing Coculture and Biosynthetic Insights. Early efforts strongly suggested the *Micromonospora* sp. as the source of **1** in cocultures and indeed, sequencing of its genome revealed BGCs representative of one type I polyketide synthase (PKS), two type II PKSs, one type III PKS, one lanthipeptide, and six hybrid clusters.[45] Also notable were ORFs encoding seven glycosyltransferases (GTs) associated with S1−S7; further functional annotations within the putative keyicin BGC (Supporting Information, Tables S3 and S4) further implicated the *Micromonospora* sp. as the producer of **1** in coculture. Sequencing of the *Rhodococcus* sp. genome,[46] on the other hand, failed to reveal any evidence of type II PKS ORFs.

With this genomic information in hand, we carried out proteomic analyses of *Micromonospora*−*Rhodococcus* cocultures and monocultures targeting only large proteins for identification; all significant proteins (or fragments thereof) were identified using PEAKS[47] software, and imported raw LC-MS/MS data were used to search the annotated *Micromonospora* sp.

and *Rhodococcus* sp. genomes[45,46] Five proteins associated with keyicin construction were identified in both coculture and *Micromonospora* sp. monoculture. Putative generic cyclase (Kyc9), dTDP-4-dehydrorhamnose 3,5-epimerase (Kyc28), and PKS cyclase (Kyc34) enzymes were detected in biological triplicate analyses, as were a phytanoyl-CoA dioxygenase (product of *kyc17*) and a 3-oxoacyl-(acyl-carrier protein). Significantly, all five *Micromonospora*-derived enzymes predicted during early genomics efforts and a DUF4440 domain-containing protein (termed Kyc51) were identified in all coculture replicates but in only one replicate of the *Micromonospora* sp. monoculture suggesting that, when confronted with the *Rhodococcus*-specific components (as during cocultures), the *Micromonospora* sp. amplifies expression of specific biosynthetic proteins associated with keyicin production.

Anthracycline BGCs and Structures Illuminate Keyicin Construction. Genomics data for both coculture organisms[45,46] allow us to glean significant biosynthetic and structural insights far exceeding our assignment of the *Micromonospora* sp. as the induced manufacturer of **1**. Indeed, these data provide significant validation of the proteomics information enabling assignment of keyicin biosynthesis to the *Micromonospora* sp. rather than the *Rhodococcus* strain. In addition to having aided the structural characterization of keyicin, nogalamycin (MIBiG: BGC0000250) and aclacinomycin A (MIBiG: BGC0000191 → BGC0000193) again serve as important reference points by way of their well-established biosynthetic gene clusters. The high degree of structural and genetic similarity between the keyicin and nogalamycin systems provide further validation, not only of the keyicin producer assignment but also key structural assignments for keyicin.

Of interest were genes located within each BGC that code for highly specific and unique functionalities that define the shared keyicin/nogalamycin benzoxocin scaffold as highlighted in Figure 7. Review of the BGCs for both natural products

Figure 7. Correlations of ORFs (and resulting gene products) to key benzoxocin linkages for keyicin versus nogalamycin aglycones. Gene and enzyme similarities across the two NP systems are color coded with arrows indicating key linkages installed. Notably only *kyc54* and *snoN* appear to be similar yet fail to carry out the same chemistry upon their respective substrates.

revealed well over 30 genes across both systems that share >60% similarity (Supporting Information, Table S3); the most interesting of these relate to benzoxocin construction. It is now well established that the products of *snoaL2* and *snoaW* hydroxylate the C-1 of a nogalamycinone intermediate[48,49] followed by glycosylation of the newly installed phenol with nogalamine by SnogD[50] and that the redox enzyme SnoK[44] carries out C–C bond formation linking the C5′ of the newly installed nogalamine *ortho* to the newly generated aryl ether linkage. Genes within the *kyc* cluster responsible for this same sequence of transformations are *kyc36/kyc51* followed by *kyc52* (glycolase) and *kyc17*, respectively (Figure 7). The structural

assignments made in advance of BGC studies are strongly supported by these genomic data.

In addition to genes dictating benzoxocin construction in both BGCs, a great many other genes have been identified within the *kyc* cluster showing strong similarity/homology to nogalamycin cluster components. A handful of these critical putative homologues are indicated in Table 1.

The benzoxocin moieties of keyicin and nogalamycin differentiate these species from the overwhelming majority of other anthracyclines. Even between keyicin and nogalamycin, however, an important differentiation is observed beyond the benzoxocin scaffold. SnoN (encoded within the nogalamycin cluster) is responsible for setting the C4′ configuration of nogalamycin via epimerization.[44] Within the *kyc* cluster, *kyc54* codes for a highly similar enzyme (71% similarity, Table 1) yet the C4′ configuration in keyicin is inverted relative to that in nogalamycin. In considering the origins of this stereochemical difference we posit that the presence of the pendant trisaccharide at C4′ in keyicin likely prohibits Kyc54-promoted epimerization. Devoid of any similar steric encumbrance, SnoN is presumably highly efficient at processing the less heavily glycosylated nogalamycin intermediate. Thus, we propose that the pendant C4′-linked sugar in keyicin prohibits Kyc54 action. This is interesting not only in the context of contrasting the keyicin and nogalamycin systems but also because it suggests that C4′ epimerization in each pathway comes at a very late stage during biosynthesis and is presumably a "post-tailoring" step; it is rare that an aglycone is subject to post-tailoring modifications. The data observed here, however, suggest that the keyicin/nogalamycin systems may be one such representative.

In addition to clear similarities between the nogalamycin and keyicin scaffolds and BGCs MIBiG accession numbers identified using antiSMASH revealed often dramatic genetic similarity to BGCs for other anthracycline natural products. The keyicin BGC was found to have very highly shared gene content to the BGCs for cinerubin B (MIBiG: BGC0000212, 88%), cosmomycin D (MIBiG: BGC0001074, 88%), arimetamycin (MIBiG: BGC0000199, 84%), kosinostatin (MIBiG: BGC0001073, 75%), and aclacinomycin (MIBiG: BGC0000191, 72%) (Supporting Information, Table S5, Figure S21 for relevant structures). To put these data into context, it is instructive to note that the BGCs for keyicin and nogalamycin (MIBiG: BGC0000250) display 52% overall similarity.

A-ring glycosylation during keyicin construction provides yet another opportunity to correlate features of the *kyc* BGC to those of other, more well-established anthracycline BGCs. During aclacinomycin construction the enzyme duo of AknS and AknT employs TDP-L-rhodosamine to tether a rhodosamine sugar to the precursor aklavinone C7-OH moiety.[56] AknK then employs TDP-2-deoxy-L-fucose to glycosylate the newly added rhodosamine moiety.[57] The resulting disaccharide can undergo another cycle of glycosylation at the hands of AknK to render the final trisaccharide.[57] Notably, within the cosmomycin D cluster, *cosK* displays 79% similarity to *aknK* and has been shown experimentally to carry out the same transformation during cosmomycin D construction as that of AknK during aclacinomycin A production.[58] Like aclacinomycin, cosmomycin D production calls for C7-OH glycosylation with L-rhodosamine. This transformation is carried out by CosG, which transfers rhodosamine to both the 7- and 10-positions of the cosmomycin aglycone; the C7-OH tethered species then serves as a substrate for fucosylation by CosK en

Table 1. Selection of Key BGC Correlations between Keyicin and Nogalamycin Clusters

kyc gene	nogalamycin BGC gene	accession no. for *kyc* gene	accession no. for nogalamycin gene	putative function for established gene product	% identity
kyc9	*snoaM*[51]	OHX01513.1	AAF01818.1	polyketide cyclase	78
kyc17	*snoK*[44]	OHX01520.1	AAF01812.1	non-heme iron α-ketoglutarate (α-KG)-dependent carbocyclase	62
kyc25	*snogE*[51−53]	OHX01526.1	AAF01809.1	GT for nogalose	62
kyc34	*snoaL*[48]	OHX01535.1	AAF01813.1	nogalonic acid methyl ester (NAME) cyclase	77.8
kyc36	*snoaW*[49,54]	OHX01536.1	AAF01810.1	putative hydroxylase (in tandem with SnoaL2)	60.7
kyc44	*snogA*[55]	OHX01543.1	AAF01819.1	amino methyltransferase	67.2
kyc51	*snoaL2*[49]	OHX01549.1	AAF01808.1	C-1 hydroxylase component (in tandem with SnogW)	63.2
kyc52	*snogD*[50,52,53]	OHX01550.1	AAF01811.1	GT (specifically, nogalamine transferase)	65
kyc54	*snoN*[44]	OHX01552.1	AAF01805.1	SnoK homologue with epimerase role	71

route to the final trisaccharide that distinguishes this species from other members of the cosmomycin family.[58] Not surprisingly, the *kyc* cluster contains three genes with moderate to good similarities to the GTs noted above; SEARCHGTr software further supported early hypotheses correlating specific chemistries to *kyc* genes.[59] For rhodosamine transfer, *kyc26* displays 43% similarity to AknT (AAF73456.1) and *kyc25* shows 56% similarity to AknS (AAF73455.1); with regard to the cosmomycin system, *kyc25* shows 60% similarity to CosG (KDN80069.1). In considering fucose transfer, AknK appears to have a number of candidate homologues within the *kyc* cluster; these genes, with accompanying similarities to AknK, include *kyc12* (48.5%), *kyc20* (52%), *kyc24* (53%), *kyc29* (50%), *kyc32* (47.7%) and *kyc52* (30%). The application of SEARCHGTr, a program specifically designed for GT analysis that takes into consideration donor and recipient active site architectures further supported the notion that GTs involved in keyicin construction bear similarity to other more well-established GTs (Supporting Information, Table S4).[59] Not surprisingly, the same *kyc* genes, with the exception of *kyc52*, with similarity to AknK also prove similar to CosK. Putative CosK homologue candidates include the keyicin biosynthetic products of *kyc12* (49.8%), *kyc20* (54%), *kyc24* (55%), *kyc29* (27.4%), and *kyc32* (48.8%). Consequently, many elements within the *kyc* BGC correlate both keyicin structural and genomics features to those of other closely related anthracyclines (Supporting Information, Table S5). These strong associations across compounds and their microbial producers provide strong support for our structural elucidation of keyicin and illuminate opportunities for potential biosynthetic engineering efforts.

Biological Activity of Keyicin. Keyicin (**1**) was screened against both Gram-positive and Gram-negative bacteria. Similar to the observed antibiotic activity of the crude extracts, keyicin exhibited selective Gram-positive activity. In addition to the growth inhibition of *Mycobacterium* sp. and *Rhodococcus* sp., keyicin inhibited *B. subtilis* and methicillin-sensitive *Staphylococcus aureus* (MSSA) at minimum inhibitory concentrations (MICs) of 8 μg/mL (9.9 μM) and 2 μg/mL (2.5 μM), respectively.

Chemical Genomics Shed Insight into Keyicin Mechanism of Action. Chemical genomics (CG) provides a means of rapidly and comprehensively assessing the pathways and processes that underlie cellular vulnerabilities to small molecules. Likewise, CG can also give insight into mechanisms of cellular resistance to such agents. We employed CG to gain broad insight into keyicin's biological mode of action. Specifically we assessed the ability of keyicin, like other anthracyclines, to induce DNA damage as reflected by

downstream effects.[60−62] Cells bearing mutations that impair the ability to sustain DNA damage are more susceptible to DNA damaging agents than are those with intact compensatory mechanisms. Accordingly, we treated a barcoded *E. coli* deletion collection with keyicin (12.5 μg/mL) and compared the resulting CG profile with those obtained from cells exposed to the well-established DNA-intercalator ethidium bromide (100 μg/mL) and methylmethanesulfonate (MMS, 0.0125%), a known DNA alkylating/damaging agent. The CG profile of keyicin was distinct from EtBr and MMS (Supporting Information, Figure S22); The profiles of EtBr and MMS had a correlation coefficient of 0.47. Keyicin, on the other hand, had a correlation of 0.11 with EtBr and 0.16 with MMS. Particularly telling was that cells bearing inactivations of *recA*, a key gene involved in DNA repair in *E. coli* and established indicator of DNA damaging agents,[63] proved particularly susceptible to the effects of EtBr and MMS yet were essentially unaffected by keyicin (Supporting Information for detailed data analysis).

Among the 20 *E. coli* mutants most sensitive to keyicin, not a single one is involved in DNA replication or repair machineries, strongly suggesting that keyicin's principal mode of action does not involve DNA damage. In fact, in considering the 46 gene mutants with significant sensitivities to keyicin (Supporting Information Table S7), no clear and significant functional enrichment is apparent to help illuminate keyicin's mode of action. Evaluations of the network around these 46 genes suggest, tentatively, that keyicin may exert antibacterial activity through modulation of fatty acid metabolism (Supporting Information). Consequently, investigations of keyicin's impact on bacterial lipid metabolism, as expeditiously brought to light by these CG studies, are clearly warranted.

■ CONCLUSIONS

The advent of interdisciplinary omics technologies has made clear that cryptic biosynthetic gene clusters encode for a significant number of as yet unknown but potentially promising antibiotics. We previously developed an approach to investigate the secondary metabolite induction resulting from interspecies interactions. Using this approach, a *Rhodococcus* sp. was found to induce production of a new antibiotic, keyicin, when cocultured with *Micromonospora* sp. Structure elucidation of keyicin was assisted by 2D ^{13}C NMR and informed, in part, by comparisons of key elements of its BGC with those of structurally related and biosynthetically characterized anthracyclines. Production of keyicin was not dependent on direct cell−cell contact, which contradicts previous reports of secondary metabolite induction by mycolic acid-containing bacteria. Keyicin was selectively active against Gram-positive bacteria

including both *Rhodococcus* sp. and *Mycobacterium* sp. The *E. coli* chemical genomics provided encouraging results surrounding a putative unique MOA for keyicin, and importantly, one that does not involve DNA damage.

METHODS

See the Supporting Information for details.

ASSOCIATED CONTENT

Ⓢ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acschembio.7b00688.

> All experimental procedures with complete spectroscopic data sets and spectra, sugar S1−S7 spectroscopic characterizations and logic along with validating modeling and DFT calculations, all chemical genomics data and noted BGC information for keyicin and nogalamycin as well as chemical structures for the noted anthracyclines (PDF)

AUTHOR INFORMATION

Corresponding Author

*Tim S. Bugni. E-mail: tbugni@pharmacy.wisc.edu.

ORCID Ⓞ

Tim S. Bugni: 0000-0002-4502-3084

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

REFERENCES

(1) Pye, C. R., Bertin, M. J., Lokey, R. S., Gerwick, W. H., and Linington, R. G. (2017) Retrospective analysis of natural products provides insights for future discovery trends. *Proc. Natl. Acad. Sci. U. S. A. 114*, 5601−5606.

(2) Yuet, K. P., and Tirrell, D. A. (2014) Chemical tools for temporally and spatially resolved mass spectrometry-based proteomics. *Ann. Biomed. Eng. 42*, 299−311.

(3) Yang, J. Y., Sanchez, L. M., Rath, C. M., Liu, X., Boudreau, P. D., Bruns, N., Glukhov, E., Wodtke, A., de Felicio, R., Fenner, A., Wong, W. R., Linington, R. G., Zhang, L., Debonsi, H. M., Gerwick, W. H., and Dorrestein, P. C. (2013) Molecular networking as a dereplication strategy. *J. Nat. Prod. 76*, 1686−1699.

(4) Watrous, J., Roach, P., Alexandrov, T., Heath, B. S., Yang, J. Y., Kersten, R. D., van der Voort, M., Pogliano, K., Gross, H., Raaijmakers, J. M., Moore, B. S., Laskin, J., Bandeira, N., and Dorrestein, P. C. (2012) Mass spectral molecular networking of living microbial colonies. *Proc. Natl. Acad. Sci. U. S. A. 109*, E1743−1752.

(5) Shih, C. J., Chen, P. Y., Liaw, C. C., Lai, Y. M., and Yang, Y. L. (2014) Bringing microbial interactions to light using imaging mass spectrometry. *Nat. Prod. Rep. 31*, 739−755.

(6) Quinn, R. A., Nothias, L. F., Vining, O., Meehan, M., Esquenazi, E., and Dorrestein, P. C. (2017) Molecular Networking As a Drug Discovery, Drug Metabolism, and Precision Medicine Strategy. *Trends Pharmacol. Sci. 38*, 143−154.

(7) Mohimani, H., Kersten, R. D., Liu, W. T., Wang, M., Purvine, S. O., Wu, S., Brewer, H. M., Pasa-Tolic, L., Bandeira, N., Moore, B. S., Pevzner, P. A., and Dorrestein, P. C. (2014) Automated genome mining of ribosomal peptide natural products. *ACS Chem. Biol. 9*, 1545−1551.

(8) Medema, M. H., Kottmann, R., Yilmaz, P., Cummings, M., Biggins, J. B., Blin, K., de Bruijn, I., Chooi, Y. H., Claesen, J., Coates, R. C., Cruz-Morales, P., Duddela, S., Dusterhus, S., Edwards, D. J., Fewer, D. P., Garg, N., Geiger, C., Gomez-Escribano, J. P., Greule, A., Hadjithomas, M., Haines, A. S., Helfrich, E. J., Hillwig, M. L., Ishida, K., Jones, A. C., Jones, C. S., Jungmann, K., Kegler, C., Kim, H. U., Kotter, P., Krug, D., Masschelein, J., Melnik, A. V., Mantovani, S. M., Monroe, E. A., Moore, M., Moss, N., Nutzmann, H. W., Pan, G., Pati, A., Petras, D., Reen, F. J., Rosconi, F., Rui, Z., Tian, Z., Tobias, N. J., Tsunematsu, Y., Wiemann, P., Wyckoff, E., Yan, X., Yim, G., Yu, F., Xie, Y., Aigle, B., Apel, A. K., Balibar, C. J., Balskus, E. P., Barona-Gomez, F., Bechthold, A., Bode, H. B., Borriss, R., Brady, S. F., Brakhage, A. A., Caffrey, P., Cheng, Y. Q., Clardy, J., Cox, R. J., De Mot, R., Donadio, S., Donia, M. S., van der Donk, W. A., Dorrestein, P. C., Doyle, S., Driessen, A. J., Ehling-Schulz, M., Entian, K. D., Fischbach, M. A., Gerwick, L., Gerwick, W. H., Gross, H., Gust, B., Hertweck, C., Hofte, M., Jensen, S. E., Ju, J., Katz, L., Kaysser, L., Klassen, J. L., Keller, N. P., Kormanec, J., Kuipers, O. P., Kuzuyama, T., Kyrpides, N. C., Kwon, H. J., Lautru, S., Lavigne, R., Lee, C. Y., Linquan, B., Liu, X., Liu, W., Luzhetskyy, A., Mahmud, T., Mast, Y., Mendez, C., Metsa-Ketela, M., Micklefield, J., Mitchell, D. A., Moore, B. S., Moreira, L. M., Muller, R., Neilan, B. A., Nett, M., Nielsen, J., O'Gara, F., Oikawa, H., Osbourn, A., Osburne, M. S., Ostash, B., Payne, S. M., Pernodet, J. L., Petricek, M., Piel, J., Ploux, O., Raaijmakers, J. M., Salas, J. A., Schmitt, E. K., Scott, B., Seipke, R. F., Shen, B., Sherman, D. H., Sivonen, K., Smanski, M. J., Sosio, M., Stegmann, E., Sussmuth, R. D., Tahlan, K., Thomas, C. M., Tang, Y., Truman, A. W., Viaud, M., Walton, J. D., Walsh, C. T., Weber, T., van Wezel, G. P., Wilkinson, B., Willey, J. M., Wohlleben, W., Wright, G. D., Ziemert, N., Zhang, C., Zotchev, S. B., Breitling, R., Takano, E., and Glockner, F. O. (2015) Minimum Information about a Biosynthetic Gene cluster. *Nat. Chem. Biol. 11*, 625−631.

(9) Krug, D., and Muller, R. (2014) Secondary metabolomics: the impact of mass spectrometry-based approaches on the discovery and characterization of microbial natural products. *Nat. Prod. Rep. 31*, 768−783.

(10) Kersten, R. D., Yang, Y. L., Xu, Y., Cimermancic, P., Nam, S. J., Fenical, W., Fischbach, M. A., Moore, B. S., and Dorrestein, P. C. (2011) A mass spectrometry-guided genome mining approach for natural product peptidogenomics,. *Nat. Chem. Biol.* 7, 794−802.

(11) Goodwin, C. R., Sherrod, S. D., Marasco, C. C., Bachmann, B. O., Schramm-Sapyta, N., Wikswo, J. P., and McLean, J. A. (2014) Phenotypic mapping of metabolic profiles using self-organizing maps of high-dimensional mass spectrometry data. *Anal. Chem.* 86, 6563−6571.

(12) Duncan, K. R., Crusemann, M., Lechner, A., Sarkar, A., Li, J., Ziemert, N., Wang, M., Bandeira, N., Moore, B. S., Dorrestein, P. C., and Jensen, P. R. (2015) Molecular networking and pattern-based genome mining improves discovery of biosynthetic gene clusters and their products from Salinispora species. *Chem. Biol.* 22, 460−471.

(13) Covington, B. C., McLean, J. A., and Bachmann, B. O. (2017) Comparative mass spectrometry-based metabolomics strategies for the investigation of microbial secondary metabolites. *Nat. Prod. Rep.* 34, 6−24.

(14) Barkal, L. J., Theberge, A. B., Guo, C. J., Spraker, J., Rappert, L., Berthier, J., Brakke, K. A., Wang, C. C., Beebe, D. J., Keller, N. P., and Berthier, E. (2016) Microbial metabolomics in open microscale platforms. *Nat. Commun.* 7, 10610.

(15) Boddy, C. N. (2014) Bioinformatics tools for genome mining of polyketide and non-ribosomal peptides. *J. Ind. Microbiol. Biotechnol.* 41, 443−450.

(16) Chakraborty, C., Doss, C. G., Patra, B. C., and Bandyopadhyay, S. (2014) DNA barcoding to map the microbial communities: current advances and future directions. *Appl. Microbiol. Biotechnol.* 98, 3425−3436.

(17) Walsh, C. T., and Fischbach, M. A. (2010) Natural Products Version 2.0: Connecting Genes to Molecules. *J. Am. Chem. Soc.* 132, 2469−2493.

(18) Fischbach, M. A., Walsh, C. T., and Clardy, J. (2008) The evolution of gene collectives: How natural selection drives chemical innovation,. *Proc. Natl. Acad. Sci. U. S. A.* 105, 4601−4608.

(19) Cantley, A. M., and Clardy, J. (2015) Animals in a bacterial world: opportunities for chemical ecology. *Nat. Prod. Rep.* 32, 888−892.

(20) Stewart, E. J. (2012) Growing unculturable bacteria. *J. Bacteriol.* 194, 4151−4160.

(21) Newman, D. J. (2016) Predominately Uncultured Microbes as Sources of Bioactive Agents. *Front. Microbiol.* 7, 1832.

(22) Cimermancic, P., Medema, M. H., Claesen, J., Kurita, K., Wieland Brown, L. C., Mavrommatis, K., Pati, A., Godfrey, P. A., Koehrsen, M., Clardy, J., Birren, B. W., Takano, E., Sali, A., Linington, R. G., and Fischbach, M. A. (2014) Insights into secondary metabolism from a global analysis of prokaryotic biosynthetic gene clusters. *Cell* 158, 412−421.

(23) Katz, M., Hover, B. M., and Brady, S. F. (2016) Culture-independent discovery of natural products from soil metagenomes. *J. Ind. Microbiol. Biotechnol.* 43, 129−141.

(24) Mora, C., Tittensor, D. P., Adl, S., Simpson, A. G., and Worm, B. (2011) How many species are there on Earth and in the ocean? *PLoS Biol.* 9, e1001127.

(25) Amaral-Zettler, L., Artigas, L. F., Baross, J., Bharathi, P. A. L., Boetius, A., Chandramohan, D., Herndl, G., Kogure, K., Neal, P., Pedrós-Alió, C., Ramette, A., Schouten, S., Stal, L., Thessen, A., de Leeuw, J., and Sogin, M. (2010) A Global Census of Marine Microbes, in *Life in the World's Oceans*, pp 221−245, Wiley-Blackwell.

(26) Adnani, N., Rajski, S. R., and Bugni, T. S. (2017) Symbiosis-inspired approaches to antibiotic discovery. *Nat. Prod. Rep.* 34, 784−814.

(27) Gubbens, J., Zhu, H., Girard, G., Song, L., Florea, B. I., Aston, P., Ichinose, K., Filippov, D. V., Choi, Y. H., Overkleeft, H. S., Challis, G. L., and van Wezel, G. P. (2014) Natural product proteomining, a quantitative proteomics platform, allows rapid discovery of bio-synthetic gene clusters for different classes of natural products. *Chem. Biol.* 21, 707−718.

(28) Van Lanen, S. G., and Shen, B. (2006) Microbial genomics for the improvement of natural product discovery. *Curr. Opin. Microbiol.* 9, 252−260.

(29) Micallef, M. L., D'Agostino, P. M., Sharma, D., Viswanathan, R., and Moffitt, M. C. (2015) Genome mining for natural product biosynthetic gene clusters in the Subsection V cyanobacteria. *BMC Genomics* 16, 669.

(30) Medema, M. H., and Fischbach, M. A. (2015) Computational approaches to natural product discovery. *Nat. Chem. Biol.* 11, 639−648.

(31) Miller, I., Chevrette, M., and Kwan, J. (2017) Interpreting Microbial Biosynthesis in the Genomic Age: Biological and Practical Considerations. *Mar. Drugs* 15, 165.

(32) Udwary, D. W., Zeigler, L., Asolkar, R. N., Singan, V., Lapidus, A., Fenical, W., Jensen, P. R., and Moore, B. S. (2007) Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. *Proc. Natl. Acad. Sci. U. S. A.* 104, 10376−10381.

(33) Florez, L. V., Biedermann, P. H., Engl, T., and Kaltenpoth, M. (2015) Defensive symbioses of animals with prokaryotic and eukaryotic microorganisms. *Nat. Prod. Rep.* 32, 904−936.

(34) Piotrowski, J. S., Simpkins, S. W., Li, S. C., Deshpande, R., McIlwain, S. J., Ong, I. M., Myers, C. L., Boone, C., and Andersen, R. J. (2015) Chemical genomic profiling via barcode sequencing to predict compound mode of action. *Methods Mol. Biol. (N. Y., NY, U. S.)* 1263, 299−318.

(35) Clardy, J., Fischbach, M. A., and Currie, C. R. (2009) The natural history of antibiotics,. *Curr. Biol.* 19, R437−441.

(36) Adnani, N., Vazquez-Rivera, E., Adibhatla, S. N., Ellis, G. A., Braun, D. R., and Bugni, T. S. (2015) Investigation of Interspecies Interactions within Marine Micromonosporaceae Using an Improved Co-Culture Approach. *Mar. Drugs* 13, 6082−6098.

(37) Hou, Y., Braun, D. R., Michel, C. R., Klassen, J. L., Adnani, N., Wyche, T. P., and Bugni, T. S. (2012) Microbial strain prioritization using metabolomics tools for the discovery of natural products. *Anal. Chem.* 84, 4277−4283.

(38) Onaka, H., Mori, Y., Igarashi, Y., and Furumai, T. (2011) Mycolic acid-containing bacteria induce natural-product biosynthesis in Streptomyces species. *Appl. Environ. Microbiol.* 77, 400−406.

(39) Shao, Y., Molnar, L. F., Jung, Y., Kussmann, J., Ochsenfeld, C., Brown, S. T., Gilbert, A. T., Slipchenko, L. V., Levchenko, S. V., O'Neill, D. P., DiStasio, R. A., Jr., Lochan, R. C., Wang, T., Beran, G. J., Besley, N. A., Herbert, J. M., Lin, C. Y., Van Voorhis, T., Chien, S. H., Sodt, A., Steele, R. P., Rassolov, V. A., Maslen, P. E., Korambath, P. P., Adamson, R. D., Austin, B., Baker, J., Byrd, E. F., Dachsel, H., Doerksen, R. J., Dreuw, A., Dunietz, B. D., Dutoi, A. D., Furlani, T. R., Gwaltney, S. R., Heyden, A., Hirata, S., Hsu, C. P., Kedziora, G., Khalliulin, R. Z., Klunzinger, P., Lee, A. M., Lee, M. S., Liang, W., Lotan, I., Nair, N., Peters, B., Proynov, E. I., Pieniazek, P. A., Rhee, Y. M., Ritchie, J., Rosta, E., Sherrill, C. D., Simmonett, A. C., Subotnik, J. E., Woodcock, H. L., 3rd, Zhang, W., Bell, A. T., Chakraborty, A. K., Chipman, D. M., Keil, F. J., Warshel, A., Hehre, W. J., Schaefer, H. F., 3rd, Kong, J., Krylov, A. I., Gill, P. M., and Head-Gordon, M. (2006) Advances in methods and algorithms in a modern quantum chemistry program package. *Phys. Chem. Chem. Phys.* 8, 3172−3191.

(40) Smith, S. G., and Goodman, J. M. (2010) Assigning stereochemistry to single diastereoisomers by GIAO NMR calculation: the DP4 probability. *J. Am. Chem. Soc.* 132, 12946−12959.

(41) Kawai, H., Hayakawa, Y., Nakagawa, M., Furihata, K., Seto, H., and Otake, N. (1987) Arugomycin, a new anthracycline antibiotic. II. Structural elucidation. *J. Antibiot.* 40, 1273−1282.

(42) Kawai, H., Hayakawa, Y., Nakagawa, M., Furihata, K., Furihata, K., Shimazu, A., Seto, H., and Otake, N. (1987) Arugomycin, a new anthracycline antibiotic. I. Taxonomy, fermentation, isolation and physico-chemical properties. *J. Antibiot.* 40, 1266−1272.

(43) Hutter, K., Baader, E., Frobel, K., Zeeck, A., Bauer, K., Gau, W., Kurz, J., Schroder, T., Wunsche, C., Karl, W., et al. (1986) Viriplanin A, a new anthracycline antibiotic of the nogalamycin group. I.

Isolation, characterization, degradation reactions and biological properties. *J. Antibiot.* 39, 1193−1204.

(44) Siitonen, V., Selvaraj, B., Niiranen, L., Lindqvist, Y., Schneider, G., and Metsa-Ketela, M. (2016) Divergent non-heme iron enzymes in the nogalamycin biosynthetic pathway. *Proc. Natl. Acad. Sci. U. S. A.* 113, 5251−5256.

(45) Adnani, N., Braun, D. R., McDonald, B. R., Chevrette, M. G., Currie, C. R., and Bugni, T. S. (2017) Draft Genome Sequence of *Micromonospora* sp. Strain WMMB235, a Marine Ascidian-Associated Bacterium. *Genome Announcements* 5, e01369-16.

(46) Adnani, N., Braun, D. R., McDonald, B. R., Chevrette, M. G., Currie, C. R., and Bugni, T. S. (2016) Complete Genome Sequence of *Rhodococcus* sp. Strain WMMA185, a Marine Sponge-Associated Bacterium. *Genome Announcements* 4, e01406-16.

(47) Ma, B., Zhang, K., Hendrie, C., Liang, C., Li, M., Doherty-Kirby, A., and Lajoie, G. (2003) PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry. *Rapid Commun. Mass Spectrom.* 17, 2337−2342.

(48) Sultana, A., Kallio, P., Jansson, A., Niemi, J., Mantsala, P., and Schneider, G. (2004) Crystallization and preliminary crystallographic data of SnoaL, a polyketide cyclase in nogalamycin biosynthesis. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* 60, 1118−1120.

(49) Siitonen, V., Blauenburg, B., Kallio, P., Mantsala, P., and Metsa-Ketela, M. (2012) Discovery of a two-component monooxygenase SnoaW/SnoaL2 involved in nogalamycin biosynthesis. *Chem. Biol.* 19, 638−646.

(50) Claesson, M., Siitonen, V., Dobritzsch, D., Metsa-Ketela, M., and Schneider, G. (2012) Crystal structure of the glycosyltransferase SnogD from the biosynthetic pathway of nogalamycin in *Streptomyces nogalater*. *FEBS J.* 279, 3251−3263.

(51) Klymyshin, D., Stephanyshyn, O., and Fedorenko, V. (2015) [THE ROLE OF *STREPTOMYCES NOGALATER* Lv65 *snoaM*, *snoaL* and *snoaE* GENES IN NOGALAMYCIN BIOSYNTHESIS]. *Tsitologiia i genetika* 49, 9−16.

(52) Siitonen, V., Claesson, M., Patrikainen, P., Aromaa, M., Mantsala, P., Schneider, G., and Metsa-Ketela, M. (2012) Identification of late-stage glycosylation steps in the biosynthetic pathway of the anthracycline nogalamycin. *ChemBioChem* 13, 120−128.

(53) Shao, L., Shi, X., Liu, W., Gao, X., Pu, T., Ma, B., and Wang, S. (2015) Inactivation and identification of three genes encoding glycosyltransferase required for biosynthesis of nogalamycin. *Biotechnol. Appl. Biochem.* 62, 765−771.

(54) Bechthold, A., and Yan, X. (2012) SnoaW/SnoaL2: a different two-component monooxygenase. *Chem. Biol.* 19, 549−551.

(55) Klimyshin, D. O., Gren, T. P., and Fedorenko, V. O. (2011) [Role of the snorA gene in nogalamycin biosynthesis by strain *Streptomyces nogalater* Lv65]. *Mikrobiologiia* 80, 490−495.

(56) Leimkuhler, C., Fridman, M., Lupoli, T., Walker, S., Walsh, C. T., and Kahne, D. (2007) Characterization of rhodosaminyl transfer by the AknS/AknT glycosylation complex and its use in reconstituting the biosynthetic pathway of aclacinomycin A. *J. Am. Chem. Soc.* 129, 10546−10550.

(57) Lu, W., Leimkuhler, C., Oberthur, M., Kahne, D., and Walsh, C. T. (2004) AknK is an L-2-deoxyfucosyltransferase in the biosynthesis of the anthracycline aclacinomycin A. *Biochemistry* 43, 4548−4558.

(58) Garrido, L. M., Lombo, F., Baig, I., Nur-e-Alam, M., Furlan, R. L., Borda, C. C., Brana, A., Mendez, C., Salas, J. A., Rohr, J., and Padilla, G. (2006) Insights in the glycosylation steps during biosynthesis of the antitumor anthracycline cosmomycin: characterization of two glycosyltransferase genes. *Appl. Microbiol. Biotechnol.* 73, 122−131.

(59) Kamra, P., Gokhale, R. S., and Mohanty, D. (2005) SEARCHGTr: a program for analysis of glycosyltransferases involved in glycosylation of secondary metabolites. *Nucleic Acids Res.* 33, W220−225.

(60) Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol. Rev.* 56, 185−229.

(61) Kizek, R., Adam, V., Hrabeta, J., Eckschlager, T., Smutny, S., Burda, J. V., Frei, E., and Stiborova, M. (2012) Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. *Pharmacol. Ther.* 133, 26−39.

(62) Gewirtz, D. A. (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. *Biochem. Pharmacol.* 57, 727−741.

(63) Bellou, S., Muenter, M., Travers, M., Leifer, B., Baig, S., Kramer, C., Qi, M., Joshi, C., Carlson, A., and Conway, C. (2016) Determination of Escherichia coli Genes Involved in Resistance to DNA Alkylating Agents. *FASEB J.* 30 (1 Suppl), 789.3.

J